Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$10.54M

FY 2025 · Annual

Net Income

-$10.41M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development126.49K833.21K1.57M2.24M2.44M
Selling, General & Admin11.64K20.94K600.19K9.64M8.1M
Operating Expenses138.13K854.15K3.94M12.24M10.54M
Depreciation & Amortization138.13K854.15K012.24M0
EBITDA00(11.43M)48K(10.41M)
EBITDA Margin—————
Operating Income(138.13K)(854.15K)(3.94M)(12.24M)(10.54M)
Operating Margin—————
Interest Income00048K125.64K
Interest Expense001.64M(4.34M)0
Other Income / Expenses00(9.13M)(4.29M)125.64K
Income Before Tax(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Net Margin—————
EPS (Basic)(0.00)(0.03)(0.44)(0.56)(0.33)
EPS (Diluted)(0.00)(0.03)(0.44)(0.56)(0.33)
Weighted Avg Shares29.61M29.61M29.61M29.54M31.65M
Weighted Avg Shares (Diluted)29.61M29.61M29.61M29.54M31.65M

TELO Earnings Waterfall · TTM

NASDAQ:TELO · Revenue to Net Income

Key Ratios

EPS$-0.29
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.1
P/S Ratio0.0

Analysis

$0 of revenue converted into -$9.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.29, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3S-3 filingOct 27, 2026
8-KCurrent reportOct 6, 2026
8-KCurrent reportSep 17, 2026
8-KCurrent reportSep 16, 2026
8-KCurrent reportSep 14, 2026

How much revenue does TELO generate?

Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported $0.00 of revenue in fiscal 2025.

Is TELO profitable?

Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported -$10.41M of net income.